Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Schizophrenia: full-pipeline trial registry
76 of 318 indexed Schizophrenia trials are currently recruiting.
Corpus placement: #23 of 28,707 conditions by registered trial count.
318 US clinical trials · 76 currently recruiting · #23 of 28,707 conditions by registered trial count
Schizophrenia: 318 US clinical trials tracked, 76 recruiting.
Schizophrenia is the subject of 318 registered US clinical trials on ClinicalTrials.gov, 76 of them currently open to new participants. 90 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is University of Maryland, Baltimore, running 14 of these trials.
Enrollment posture brief
Registry condition schizophrenia
OPEN 76 | RECR 24% | LATE 90 | EARLY 87 | RANK #23 | SPON 14
Volume-matched condition peers
Nearest open-share peer: Dehydration (24% recruiting · 21 trials)
Schizophrenia lists 76 open slots (24% of 318 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Schizophrenia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Schizophrenia is recruiting below its size-band peers.
76 of 318 indexed trials (23.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Schizophrenia trials is spread across many organizations.
University of Maryland, Baltimore accounts for 14 of 318 trials (4.4%). 129 distinct sponsors appear on at least one study for this condition label.
-
Typical Schizophrenia enrolment sits around 83 participants.
Median target enrolment is 83 among the 316 trials that report a genuine target (sentinel values excluded). 169 of those (53.5%) plan for fewer than 100 participants.
-
Schizophrenia research is mostly interventional.
290 interventional and 28 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
318 total, page 6 of 7
Texting for Relapse Prevention
Center for Innovative Public Health Research
NCT02819349
Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects
Omeros Corporation
NCT01952132
Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)
University of Maryland, Baltimore
NCT03183609
Self-Management Therapy for Youth With Schizophrenia
National Institute of Mental Health (NIMH)
NCT00000387
Peer-delivered and Technology-Assisted Integrated Illness Management and Recovery
Dartmouth-Hitchcock Medical Center
NCT04481737
Cognitive Remediation and Social Skills Training in Schizophrenia
The University of Texas Health Science Center at San Antonio
NCT00223535
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization
NCT02411695
Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia
Taisho Pharmaceutical Co.
NCT00876304
Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
Northwell Health
NCT00042224
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
Massachusetts General Hospital
NCT00455702
Treating Smokers With Mental Illness
University of Minnesota
NCT03822416
Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients
Washington University School of Medicine
NCT00501163
Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
Harvard Medical School (HMS and HSDM)
NCT00169065
Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization
NCT03150771
Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade
Northwell Health
NCT00225498
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
Endo Pharmaceuticals
NCT01774435
Minocycline and Tobacco Craving in Smokers With Schizophrenia
University of Maryland, Baltimore
NCT02968602
A Comparison of Two Cognitive Batteries in People With Schizophrenia
North Suffolk Mental Health Association
NCT00499044
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
Neurocrine Biosciences
NCT03359785
Motivation and Skills Support (MASS)
Boston University Charles River Campus
NCT03404219
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
Otsuka Pharmaceutical Development & Commercialization
NCT05402111
Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia
Shire
NCT01457339
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Massachusetts General Hospital
NCT02594696
Once-Daily Asenapine for Schizophrenia
Duke University
NCT01549041
A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness
University Hospitals Cleveland Medical Center
NCT02085447
Efficacy of Pimozide Augmentation for Clozapine Partial Response
Yale University
NCT00374244
Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia
Durham VA Medical Center
NCT00560937
Prebiotic Treatment in People With Schizophrenia - Pilot Study
University of Maryland, Baltimore
NCT03617783
Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia
Veterans Medical Research Foundation
NCT00546403
Financial Incentives to Improve Medication Adherence
Northwell Health
NCT04191876
Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia
Massachusetts General Hospital
NCT00833547
Rt-fMRI Neurofeedback and AH in Schizophrenia
Harvard Medical School (HMS and HSDM)
NCT03504579
Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
Massachusetts General Hospital
NCT00595504
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
University of Maryland, Baltimore
NCT01614093
Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
North Suffolk Mental Health Association
NCT00351000
Varenicline and Smoking Cessation in Schizophrenia
University of Minnesota
NCT01111149
Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia
Yale University
NCT00793780
Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar or Schizophrenia Illness
Stanford University
NCT03935854
A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
Otsuka Pharmaceutical Development & Commercialization
NCT04865835
Neuroendocrine and Immune Response to Stress in Schizophrenia
University of Maryland, Baltimore
NCT01975584
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
National Institute of Mental Health (NIMH)
NCT00802100
NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia
North Shore Therapeutics
NCT06653829
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
Research Foundation for Mental Hygiene
NCT00488163
Galantamine for Cognition in People With Schizophrenia
North Suffolk Mental Health Association
NCT00320736
Brain Stimulation and Cognitive Training - Efficacy
University of Michigan
NCT05111548
M1 Schizophrenia PET Study
Yale University
NCT05105542
A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia
Abbott
NCT01545310
In Vivo Imaging of Therapeutic Electric Current Flow
University of Florida
NCT02453763
Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study
University of Pittsburgh
NCT00129441
Biomarkers in Schizophrenia
Nathan Kline Institute for Psychiatric Research
NCT00817336
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 40 |
| Phase 3 | 50 |
| Phase 4 | 40 |
Top Sponsors
Named interventions
Most-linked intervention names on Schizophrenia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Schizophrenia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Schizophrenia page
318 registered trials, 76 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 76 Schizophrenia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Maryland, Baltimore sponsors the most Schizophrenia trials on record, review their full trial history before evaluating a specific study. See University of Maryland, Baltimore's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Schizophrenia condition card totals 318 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.